Presentations made painless

Company > Arcturus Therapeutics Holdings Inc: Business Model, SWOT Analysis, and Competitors 2023

Arcturus Therapeutics Holdings Inc: Business Model, SWOT Analysis, and Competitors 2023

Published: Mar 10, 2023

Inside This Article


    Arcturus Therapeutics Holdings Inc is a prominent biotechnology company that utilizes RNA medicines to treat a wide range of diseases. This blog article will delve into the detailed analysis of their business model, conducting a SWOT analysis to identify their strengths, weaknesses, opportunities, and threats. Additionally, we will explore their competitors in the industry and provide insights into the company's position in the market by 2023. Join us as we uncover the key factors shaping Arcturus Therapeutics' success and the challenges they may face in the near future.

    What You Will Learn:

    • Who owns Arcturus Therapeutics Holdings Inc and how the ownership structure of the company is organized.
    • The mission statement of Arcturus Therapeutics Holdings Inc and how it guides the company's operations and goals.
    • How Arcturus Therapeutics Holdings Inc generates revenue and the various sources of income for the company.
    • An explanation of the Business Model Canvas of Arcturus Therapeutics Holdings Inc, highlighting its key components and how they contribute to the company's success.
    • The main competitors of Arcturus Therapeutics Holdings Inc and an overview of their offerings and market presence.
    • A SWOT analysis of Arcturus Therapeutics Holdings Inc, examining the company's strengths, weaknesses, opportunities, and threats in the industry.

    Who owns Arcturus Therapeutics Holdings Inc?

    Major Shareholders

    Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA (mRNA) medicines company, has a diverse ownership structure. While the company has numerous shareholders, some major stakeholders hold a significant portion of the company's outstanding shares.

    One of the major stakeholders is Johnson & Johnson Innovation, the strategic venture capital arm of the renowned healthcare company. Johnson & Johnson Innovation has made a substantial investment in Arcturus Therapeutics, demonstrating their confidence in the company's mRNA technology and potential for future growth.

    Another significant shareholder is Venrock Healthcare Capital Partners, a prominent venture capital firm specializing in healthcare investments. Venrock Healthcare Capital Partners has a strong track record of supporting innovative healthcare companies, and their investment in Arcturus Therapeutics indicates their belief in the company's potential to revolutionize the field of mRNA therapeutics.

    Insider Ownership

    In addition to external stakeholders, Arcturus Therapeutics also has notable insider ownership. The company's executive team, including its founders and key management personnel, holds a significant stake in the company. This aligns their interests with those of other shareholders, ensuring that they are motivated to drive the company's success and maximize shareholder value.

    Institutional Ownership

    Arcturus Therapeutics also boasts a considerable level of institutional ownership. Various institutional investors, including mutual funds, pension funds, and investment firms, hold a substantial number of shares in the company. These institutional investors conduct thorough due diligence and analysis before investing, indicating their confidence in Arcturus Therapeutics' business model and future prospects.


    Arcturus Therapeutics Holdings Inc. has a diverse ownership structure, with major shareholders including Johnson & Johnson Innovation and Venrock Healthcare Capital Partners. The company also has significant insider ownership, ensuring that the executive team is aligned with shareholder interests. Additionally, institutional investors hold a considerable stake in the company, further highlighting the confidence in Arcturus Therapeutics' potential. This diverse ownership base contributes to the company's stability and growth trajectory, positioning it for success in the mRNA therapeutics industry.

    What is the mission statement of Arcturus Therapeutics Holdings Inc?

    The Mission Statement of Arcturus Therapeutics Holdings Inc.

    Arcturus Therapeutics Holdings Inc. is a leading clinical-stage messenger RNA (mRNA) medicines company focused on the discovery, development, and commercialization of innovative therapies. The company's mission statement reflects its commitment to revolutionizing the treatment landscape by harnessing the power of mRNA technology to provide safe, effective, and transformative therapies for patients in need.

    Developing mRNA Medicines for Unmet Medical Needs

    Arcturus Therapeutics aims to develop mRNA medicines that address unmet medical needs across a wide range of therapeutic areas. By leveraging the unique capabilities of mRNA, the company seeks to provide novel treatments for diseases that have been traditionally difficult to target using conventional approaches.

    Pioneering mRNA Therapeutics

    The mission statement emphasizes Arcturus Therapeutics' dedication to pioneering mRNA therapeutics. The company is at the forefront of mRNA technology, utilizing its proprietary lipid nanoparticle delivery system, LUNAR''. This innovative platform allows for the efficient and targeted delivery of mRNA therapeutics to specific tissues and cells, opening up new possibilities for precision medicine.

    Collaboration and Partnerships

    Arcturus Therapeutics understands the importance of collaboration and partnerships in advancing the field of mRNA therapeutics. The company actively seeks collaborations with leading academic institutions, pharmaceutical companies, and biotechnology firms to accelerate the development and commercialization of its innovative therapies. By fostering strategic alliances, Arcturus Therapeutics aims to maximize the potential of mRNA technology and bring transformative treatments to patients worldwide.

    Commitment to Patients

    At the core of Arcturus Therapeutics' mission statement is its unwavering commitment to patients. The company strives to improve the lives of individuals suffering from debilitating diseases by developing safe and effective mRNA medicines. Arcturus Therapeutics recognizes the urgency of addressing unmet medical needs and works tirelessly to bring innovative therapies to patients as quickly as possible.

    Advancing the Field of mRNA Therapeutics

    Arcturus Therapeutics is not only focused on developing its own pipeline of mRNA therapeutics but also on advancing the field as a whole. The company actively engages in research and development efforts to expand the potential applications of mRNA technology. By pushing the boundaries of science and innovation, Arcturus Therapeutics aims to unlock new therapeutic possibilities and contribute to the broader field of mRNA therapeutics.

    In summary, the mission statement of Arcturus Therapeutics Holdings Inc. reflects the company's commitment to developing and commercializing innovative mRNA medicines to address unmet medical needs. Through pioneering research, collaboration, and a patient-centric approach, Arcturus Therapeutics seeks to revolutionize the treatment landscape and improve the lives of patients worldwide.

    How does Arcturus Therapeutics Holdings Inc make money?


    Arcturus Therapeutics Holdings Inc is a biotechnology company that specializes in the discovery, development, and commercialization of therapeutic products based on its proprietary mRNA technology. With a focus on developing treatments for rare diseases, liver diseases, and respiratory diseases, the company has established various revenue streams to generate income. This section will delve into the primary ways in which Arcturus Therapeutics makes money.

    Licensing and Collaboration Agreements

    One of the key revenue streams for Arcturus Therapeutics is through licensing and collaboration agreements with pharmaceutical and biotechnology companies. These agreements typically involve the granting of rights to Arcturus' proprietary mRNA technology for the development and commercialization of specific therapeutic products. In return, Arcturus receives upfront payments, milestone payments upon achieving certain development or regulatory milestones, and royalties on net sales of licensed products.

    Through these licensing and collaboration agreements, Arcturus not only generates immediate income but also has the potential to earn significant revenue in the long term as its partner companies progress through clinical trials and eventually commercialize the licensed products. This approach allows Arcturus to leverage its innovative mRNA technology while sharing the risks and costs of development with its partners.

    Grant Funding

    Another important source of revenue for Arcturus Therapeutics is grant funding from government agencies, foundations, and other organizations. As a biotechnology company engaged in research and development, Arcturus is eligible for various grants aimed at supporting innovative technologies and therapeutic advancements. These grants provide financial support for specific projects or research efforts, helping Arcturus to advance its pipeline and develop potential treatments for unmet medical needs.

    By securing grant funding, Arcturus not only receives necessary capital but also validates the scientific and commercial potential of its mRNA platform. Furthermore, these grants often come with additional benefits such as access to research networks, collaboration opportunities, and increased visibility within the biotech community.

    Strategic Partnerships and Joint Ventures

    Arcturus Therapeutics also generates revenue through strategic partnerships and joint ventures with other biopharmaceutical companies. These partnerships can take various forms, including co-development agreements, co-promotion agreements, and joint ventures focused on specific therapeutic areas or target indications.

    Through strategic partnerships, Arcturus gains access to additional resources, expertise, and funding to accelerate the development and commercialization of its product candidates. In return, the partnering companies benefit from Arcturus' mRNA technology platform and its potential to revolutionize the treatment of diseases. These collaborations often involve upfront payments, milestone payments, and royalties, providing Arcturus with a steady income stream while expanding its reach and market presence.


    Arcturus Therapeutics Holdings Inc utilizes a multi-faceted approach to generate revenue and sustain its operations. By leveraging its proprietary mRNA technology, the company engages in licensing and collaboration agreements, securing grant funding, and forming strategic partnerships and joint ventures. Through these diverse revenue streams, Arcturus continues to advance its innovative pipeline and bring potential life-changing therapies to patients suffering from rare, liver, and respiratory diseases.

    Arcturus Therapeutics Holdings Inc Business Model Canvas Explained

    Introduction to Arcturus Therapeutics Holdings Inc

    Arcturus Therapeutics Holdings Inc is a leading biopharmaceutical company that specializes in the discovery and development of RNA medicines. With a strong focus on messenger RNA (mRNA) therapeutics, Arcturus aims to revolutionize the way diseases are treated by harnessing the potential of RNA.

    What is the Business Model Canvas?

    The Business Model Canvas is a strategic management tool that provides a comprehensive overview of a company's key activities, resources, and value propositions. It helps visualize the various components of a business model and how they interact to create value for customers and generate revenue.

    Key Components of Arcturus Therapeutics' Business Model Canvas

    1. Customer Segments: Arcturus primarily targets patients suffering from rare diseases, liver diseases, and respiratory conditions. By identifying these specific customer segments, the company can tailor its RNA medicines to address their unique needs.

    2. Value Propositions: Arcturus offers innovative mRNA therapeutics that have the potential to provide targeted and personalized treatments for various diseases. The company's value proposition lies in its ability to develop safe and effective RNA medicines that can improve patient outcomes and quality of life.

    3. Channels: Arcturus utilizes various channels to reach its customers and distribute its products. These channels include partnerships with pharmaceutical companies, collaborations with research institutions, and direct engagement with healthcare providers.

    4. Customer Relationships: Arcturus builds and maintains strong relationships with its customers by focusing on patient-centricity and actively seeking feedback from patients and healthcare professionals. This helps the company understand the evolving needs of its customers and continuously improve its products and services.

    5. Revenue Streams: Arcturus generates revenue through several streams, including licensing agreements, collaborations, and partnerships. By leveraging its innovative mRNA technology and expertise, the company can secure licensing deals and form strategic alliances to monetize its intellectual property.

    6. Key Activities: Arcturus invests heavily in research and development activities to discover and develop novel mRNA therapeutics. The company also focuses on clinical trials, regulatory approvals, and manufacturing to ensure the successful commercialization of its products.

    7. Key Resources: The key resources of Arcturus include its scientific knowledge, intellectual property portfolio, research and development capabilities, and a team of highly skilled researchers and professionals. These resources enable the company to innovate and stay at the forefront of mRNA therapeutics.

    8. Key Partnerships: Arcturus collaborates with pharmaceutical companies, research institutions, and other biotech firms to leverage their expertise, resources, and distribution networks. These strategic partnerships help accelerate the development and commercialization of Arcturus' mRNA therapeutics.

    9. Cost Structure: Arcturus incurs costs related to research and development, clinical trials, manufacturing, regulatory compliance, and marketing. The company strategically manages its costs to ensure efficient allocation of resources and maximize profitability.


    Arcturus Therapeutics Holdings Inc's Business Model Canvas provides a comprehensive overview of how the company creates value for its customers and stakeholders. By focusing on innovation, collaboration, and patient-centricity, Arcturus aims to revolutionize the treatment of diseases through its mRNA therapeutics. With its strategic partnerships and key resources, the company is well-positioned to drive the development and commercialization of innovative RNA medicines.

    Which companies are the competitors of Arcturus Therapeutics Holdings Inc?

    Overview of Arcturus Therapeutics Holdings Inc.

    Arcturus Therapeutics Holdings Inc. is a leading clinical-stage messenger RNA (mRNA) medicines company. They focus on the discovery, development, and commercialization of innovative RNA therapeutics for various diseases. Arcturus utilizes their proprietary lipid nanoparticle (LNP) and mRNA-based drug delivery technologies to develop cutting-edge therapies.

    Competitors in the mRNA Therapeutics Space

    While Arcturus Therapeutics Holdings Inc. is a prominent player in the mRNA therapeutics industry, they do face competition from other companies operating in the same space. Some of the key competitors of Arcturus are:

    1. Moderna Therapeutics

    Moderna Therapeutics is a pioneer in the field of mRNA therapeutics and is considered one of the leading competitors of Arcturus. They have developed a diverse pipeline of mRNA-based therapies targeting various diseases, including infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Moderna's mRNA platform and extensive research capabilities make them a formidable competitor in the market.

    2. BioNTech SE

    BioNTech SE is another significant competitor of Arcturus Therapeutics Holdings Inc. They have established themselves as a global biotechnology company specializing in mRNA-based immunotherapies for cancer treatment. With a strong focus on personalized medicine, BioNTech has developed multiple mRNA vaccine candidates and therapies for various types of cancer. Their innovative approaches and strategic partnerships have positioned them as a key player in the industry.

    3. CureVac AG

    CureVac AG is a leading clinical-stage biopharmaceutical company that focuses on developing mRNA-based therapeutics. They have a diverse pipeline of mRNA vaccines, antibodies, and immunotherapies for various diseases, including infectious diseases, oncology, and rare diseases. CureVac's proprietary mRNA technology platform and extensive research collaborations contribute to their competitiveness in the market.

    4. Translate Bio

    Translate Bio is a clinical-stage mRNA therapeutics company that develops transformative medicines to treat diseases caused by protein or gene dysfunction. They have a broad pipeline of mRNA therapeutics targeting genetic disorders, pulmonary diseases, and various other indications. Translate Bio's differentiated mRNA platform and strategic partnerships make them a notable competitor in the field.

    5. Pfizer Inc.

    Pfizer Inc., a renowned pharmaceutical company, has also entered the mRNA therapeutics arena with their collaboration with BioNTech SE. Together, they developed the first authorized mRNA-based COVID-19 vaccine. With their extensive resources, global reach, and expertise in vaccine development, Pfizer represents a formidable competitor for Arcturus Therapeutics Holdings Inc.


    Arcturus Therapeutics Holdings Inc. operates in a competitive landscape alongside other prominent players in the mRNA therapeutics industry. Companies like Moderna Therapeutics, BioNTech SE, CureVac AG, Translate Bio, and Pfizer Inc. pose significant competition to Arcturus. Despite the competition, the growing demand for mRNA-based therapies and the unique capabilities of each company contribute to the overall advancement of this exciting field.

    Arcturus Therapeutics Holdings Inc SWOT Analysis


    • Innovative technology: Arcturus Therapeutics Holdings Inc is known for its innovative approach to developing RNA-based therapeutics. The company's proprietary LUNAR'' delivery platform allows for efficient and targeted delivery of RNA molecules into cells, enhancing the effectiveness of therapeutic treatments.
    • Strong pipeline: Arcturus has a robust pipeline of RNA-based therapeutics targeting various diseases, including rare genetic disorders, liver diseases, and respiratory diseases. The company has several programs in different stages of development, providing potential revenue streams in the future.
    • Strategic partnerships: Arcturus has established strategic partnerships with leading pharmaceutical companies, including Janssen Pharmaceuticals, Ultragenyx Pharmaceutical, and Takeda Pharmaceutical. These partnerships provide validation of the company's technology and access to additional resources, expertise, and potential licensing opportunities.
    • Strong management team: The company is led by a team of experienced executives with a track record of success in the pharmaceutical industry. The management team's expertise in RNA-based therapeutics and drug development is a key strength for Arcturus.


    • Dependency on a single technology platform: While Arcturus' LUNAR'' delivery platform has shown promising results, the company's success heavily relies on the effectiveness and acceptance of this technology. Any setbacks or limitations in the platform could significantly impact the company's ability to develop successful therapeutics.
    • Limited market presence: Compared to some of its competitors, Arcturus has a relatively smaller market presence and brand recognition. This could potentially limit the company's ability to attract partnerships, secure funding, or compete with larger pharmaceutical companies.
    • Regulatory and clinical trial risks: Like any other biopharmaceutical company, Arcturus faces regulatory risks associated with obtaining necessary approvals for its therapeutics. Additionally, the success of clinical trials is uncertain and subject to various factors, including safety and efficacy concerns, which could lead to delays or failures.


    • Growing demand for RNA-based therapeutics: The field of RNA-based therapeutics is rapidly evolving, and there is an increasing demand for innovative treatments targeting genetic disorders, cancer, and other diseases. Arcturus is well-positioned to capitalize on this opportunity with its advanced RNA delivery platform and strong pipeline.
    • Expansion into new therapeutic areas: Arcturus has the potential to expand its focus beyond its current therapeutic areas, such as rare genetic disorders and liver diseases. The versatility of RNA-based therapeutics allows for targeting a wide range of diseases, providing opportunities for Arcturus to leverage its technology in new therapeutic areas.
    • Licensing and partnership opportunities: Arcturus' strong partnerships with leading pharmaceutical companies open doors for potential licensing deals and collaborations. These partnerships can provide access to additional resources, funding, and expertise, enabling Arcturus to accelerate the development and commercialization of its therapeutics.


    • Intense competition: The biopharmaceutical industry is highly competitive, with numerous companies developing RNA-based therapeutics and other innovative treatments. Arcturus faces competition from both established pharmaceutical companies and emerging biotech startups. This competitive landscape could potentially impact the company's market share and growth prospects.
    • Intellectual property challenges: Arcturus relies on its intellectual property rights to protect its technology and pipeline. However, there is a risk of intellectual property challenges, such as patent disputes or infringement claims, which could impact the company's ability to commercialize its products or secure licensing deals.
    • Market volatility and economic conditions: The biopharmaceutical industry is subject to market volatility and economic conditions, which can affect funding availability, investor sentiment, and the overall demand for healthcare products. Economic downturns or changes in healthcare policies can impact Arcturus' financial performance and growth trajectory.

    Key Takeaways

    • Arcturus Therapeutics Holdings Inc is owned by a combination of institutional investors, including Fidelity Management & Research Company and Vanguard Group.
    • The mission statement of Arcturus Therapeutics Holdings Inc is to develop and deliver innovative RNA medicines to improve the lives of patients suffering from serious diseases.
    • Arcturus Therapeutics Holdings Inc generates revenue through partnerships, collaborations, and licensing agreements with pharmaceutical companies, as well as through grants, royalties, and milestone payments.
    • The Business Model Canvas of Arcturus Therapeutics Holdings Inc encompasses key elements such as value proposition, customer segments, channels, revenue streams, and key activities.
    • Competitors of Arcturus Therapeutics Holdings Inc include companies like Moderna Therapeutics, BioNTech, and Translate Bio.
    • In a SWOT analysis, Arcturus Therapeutics Holdings Inc's strengths lie in its innovative RNA technology and strong partnerships, while its weaknesses include a limited product pipeline. Opportunities include the growing demand for RNA medicines, but threats include potential competition and regulatory challenges.


    In conclusion, Arcturus Therapeutics Holdings Inc is a biotech company that is owned by a group of investors and executives. Its mission statement is to develop breakthrough RNA medicines to treat diseases and improve patient lives. The company generates revenue through various sources, including partnerships, collaborations, and grants. The Arcturus Therapeutics Business Model Canvas outlines the key activities, resources, and partnerships that contribute to its success. As for competitors, some notable companies in the field include Moderna, BioNTech, and CureVac. Finally, a SWOT analysis of Arcturus Therapeutics reveals its strengths in innovative technology and strategic collaborations, while also highlighting potential weaknesses and opportunities for growth in the dynamic biotech industry. Overall, Arcturus Therapeutics is poised to make significant advancements in the field of RNA medicines and contribute to the improvement of global healthcare.


    Should I buy Arcturus Therapeutics?

    I'm sorry, but as an AI language model, I cannot provide personalized investment advice. The decision of whether to buy or sell a specific stock like Arcturus Therapeutics should be based on thorough research, analysis of the company's financial health, future prospects, and your own investment goals and risk tolerance. It's always advisable to consult with a financial advisor or do your own research before making any investment decisions.

    Is Arcturus a buy?

    I'm sorry, but as an AI language model, I don't have access to real-time financial data or the ability to provide investment advice. The decision to buy or sell a specific stock like Arcturus would depend on various factors, including your individual financial goals, risk tolerance, and market analysis. It is always recommended to do thorough research, consult with a financial advisor, and consider your own circumstances before making any investment decisions.

    Who are Arcturus competitors?

    Some of Arcturus' competitors in the field of gene editing and cell therapy include:

    1. CRISPR Therapeutics: A biotechnology company focused on developing gene-based medicines using CRISPR-Cas9 technology.

    2. Editas Medicine: A genome editing company that develops therapeutics using CRISPR and other gene editing technologies.

    3. Intellia Therapeutics: A biotechnology company that focuses on developing CRISPR/Cas9-based therapies for genetic diseases.

    4. Sangamo Therapeutics: A clinical-stage biotechnology company that develops gene and cell therapies using zinc finger nuclease (ZFN) and other genome editing technologies.

    5. bluebird bio: A biotechnology company specializing in gene and cell therapies for severe genetic diseases and cancer.

    6. Beam Therapeutics: A biotechnology company that develops precision genetic medicines using base editing technology.

    7. Cellectis: A clinical-stage biopharmaceutical company that focuses on developing gene-edited CAR-T cell therapies for cancer.

    8. Precision Biosciences: A biotechnology company that develops gene editing technologies, including the proprietary ARCUS genome editing platform.

    9. CRISPR Genomics: A biotechnology company that offers CRISPR-based research tools and services for gene editing and genome engineering.

    10. Horizon Discovery: A company that provides gene editing and gene modulation tools and services for research and drug discovery applications.

    What is the price target for Arcturus?

    As an AI language model, I don't have access to real-time financial data. The price target for Arcturus Therapeutics, a biotech company focused on developing RNA medicines, can vary depending on the opinions of different analysts and market conditions. It is recommended to consult financial experts, analysts' reports, or reliable financial websites for the most up-to-date and accurate price targets for Arcturus.

    Want to create a presentation now?

    • instantly

      Instantly Create A Deck

      Let PitchGrade do this for me

    • smile

      Hassle Free

      We will create your text and designs for you. Sit back and relax while we do the work.

    Explore More Content